However, if doctors think the cancer may have spread to the lymph nodes, they usually recommend a much more serious surgery ...

Insurance-related barriers are delaying timely and essential bariatric and metabolic surgery for patients living with severe ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

Little Rock's CHI St. Vincent Infirmary has received accreditation for metabolic and bariatric surgery. The hospital was ...

The FDA has approved AstraZeneca’s IMFINZI combined with standard FLOT chemotherapy for adults with resectable, early-stage ...

FDA approves AstraZeneca's Imfinzi plus FLOT for early gastric and GEJ cancers after Phase 3 data show strong event-free and ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

The evidence-based recommendations address how radiation therapy should be used across the spectrum of gastric cancer, from resectable locoregional to metastatic disease.

AstraZeneca said it received U.S. approval for Imfinzi as a treatment for patients with early gastric and gastroesophageal cancers, expanding the indication label for one of its bestselling oncology ...

The US FDA has approved a durvalumab (Imfinzi, AstraZeneca)-based regimen for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Specifically, durvalumab, an ...

Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.